Dra. Ana Aparicio

MD Anderson Cancer Center Houston, Houston, Texas


See curriculum
Dr. Aparicio is an Associate Professor in the Genitourinary Medical Oncology Department at the University of Texas MD Anderson Cancer Center. She earned her medical degree from Universidad Autonoma de Madrid in Madrid, Spain. Following her residency at West Los Angeles VA Medical Center, UCLA School of Medicine, she completed a fellowship in medical Oncology and Hematology at USC/Norris Comprehensive Cancer Center, LAC Medical Center, Keck School of Medicine, Los Angeles, CA.

Dr. Aparicio has focused her research efforts on characterizing a clinically distinct subset of the advanced prostate cancer disease, the aggressive variant prostate cancers, which is estimated to constitute up to one third of the disease. She believes that her ongoing research will ultimately enhance the care she is able to provide to her clinical patients and to those in the community afflicted with the same disease.

Ir arriba


Dr. Jorge Aparicio

Hospital Universitari i Politècnic la Fe, Valencia


See curriculum
Doctor en Medicina por la Universidad de Valencia y especialista en Oncología Médica.
Jefe de Sección (unidad de tumores digestivos y musculoesqueléticos) en el Hospital Universitario y Politécnico La Fe, Valencia.
Miembro actual de la Junta Directiva de la Sociedad Española de Oncología Médica (SEOM).
También miembro de las sociedades científicas European Society of Medical Oncology (ESMO) y American Society of Clinical Oncology (ASCO), así como de los grupos cooperativos Grupo Español para el Estudio y Tratamiento de los Tumores Digestivos (TTD), Grupo Español de Tumores Germinales (GG) y Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD)
Investigador principal en más de 70 ensayos clínicos, autor de más de 120 ponencias o conferencias en reuniones científicas y autor de más de 80 artículos en revistas internacionales de oncología.

Ir arriba


Dr. Gerhardt Attard

The Institute of Cancer Research and the Royal Marsden, Shutton, UK


See curriculum
Dr Attard is a Cancer Research UK Clinician Scientist and Team Leader at The Institute of Cancer Research and an Honorary Medical Oncology Consultant at the Royal Marsden NHS Foundation Trust, London, UK. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010. His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and a co-author of more than 100 peer-reviewed manuscripts, including several important papers on advanced prostate cancer. Dr Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investor Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. Dr Attard sits on a number of advisory boards and the editorial board of Annals of Oncology.
Ir arriba


Dr. Álvaro Aytes

Institut Català d’Oncologia, Barcelona


See curriculum
Dr. Álvaro Aytes is the Group Leader of the Resistance and Progression mechanisms in Prostate Cancer group at IDIBELL. Dr. Aytes´s laboratory aims at uncovering new mechanisms driving cancer progression and metastasis and to elucidate how these contribute to the emergence of therapeutic resistance. The lab´s main focus is on prostate cancer, for which we utilize genetically-engineered mice (GEM) to model relevant molecular alterations and gene regulatory network-based approaches to identify actionable targets that can be validated in preclinical models.
Ir arriba


Dr. Joaquim Bellmunt

Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA


See curriculum
Dr. Joaquim Bellmunt is Associate Professor of Medicine at Harvard Medical School and Attending Physician of Solid Tumor Oncology at Dana-Farber Cancer Institute (DFCI). He also serves as the Director of the Bladder Cancer Center at DFCI and Dana-Farber/Brigham and Women’s Cancer Center, Harvard University, Boston working as part of a multidisciplinary team to provide complete care for patients with genitourinary malignancies. He is past chairman of the Committee of Advanced Bladder Cancer in the European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group (EORTC-GU). He is co-founder and has been President of the Spanish Group for Treatment of Genitourinary Tumors (SOGUG). Dr. Bellmunt’s efforts have largely centered on improving the care of patients with genitourinary malignancies focusing on bladder and renal cell carcinoma.

His areas of interest in genitourinary oncology include the development of drugs directed to novel therapeutic targets and early clinical and translational research in the field of growth factor receptors and angiogenesis. While his research interests are focused on bladder cancer, he has extensive experience treating prostate, penile and kidney cancer. He serves on International committees focused on improving the treatments of genitourinary and bladder cancers. He is a member of the Editorial Board of the Journal of Clinical Oncology and European Urology.

He has been chairing two of the larger multicenter international trials of new drugs in the treatment of bladder cancer, in one of them, leading to the establishment of a new drug for bladder cancer patients. Dr. Bellmunt’s research focuses on clinical trials with aims to improve the treatment of patients with advanced bladder (urothelial) tumors as well as the development of novel agents for this disease. Dr. Bellmunt is currently involved in collaborative efforts with basic scientists to analyze clinical, tissue, and biomarkers to optimize the administration of targeted therapeutic agents in bladder cancer.

Ir arriba


Dr. Jörg Beyer

Hospital Universitario Zürich, Zürich


See curriculum
1982-1989 Undergraduate Medical Training, Free University Berlin, Germany
1989-1999 Postgraduate Training, Charité University, Berlin Germany
1999-2005 Associate Professor, University of Marburg, Germany,
2005-2007 Medical Director, Community Hospital Network, Ravensburg, Germany
2007-2013 Head of Department, Vivantes Klinikum Am Urban, Berlin, Germany
Current Position
Since 2013 Consultant Oncologist, University Hospital Zurich, Switzerland
Main Research Interest
Germ-cell cancer
Since September 2013 I serve as a consultant at the department of oncology at the University Hospital Zurich. Apart from teaching activities in the local curriculum, my clinical focus is on lymphomas, sarcomas and urogenital tumors with medical ethics as another special interest. I am also affiliated and teach at the Wilsede School of Oncology in Germany, the European School of Oncology and at seminars of the European Society of Medical Oncology in addition to presentations and educationals at international congresses.
Between 1982 and 1989 I received my medical training at the Free University Berlin, Germany, at the Royal Free Hospital in London, UK, and the Brown University in Rhode Island, US. My postgraduate medical training in internal medicine, hematology, oncology and palliative care took place at the Charité University Hospital, Berlin, Germany, between 1989 and 1999. From 1999 until 2005 I held a post as associate professor at the University Hospital in Marburg, Germany. From 2005 until 2007 I was appointed medical director at a community hospital in Ravensburg, Germany, and from 2007 until 2013 I was head of the department of hematology and oncology at the Vivantes Klinikum Am Urban in Berlin, Germany, and director of the Vivantes Cancer Center.
I am author and co-author of more than 160 original articles, reviews and book chapters.
Ir arriba


Dr. James Brugarolas

University of Texas, Texas, USA


See curriculum
James Brugarolas, M.D., Ph.D. is the leader of the Kidney Cancer Program and the Principal Investigator of the UT Southwestern Kidney Cancer SPORE. He received his medical degree from the University of Navarra (1993), and his Ph.D. from the Massachusetts Institute of Technology (1998). He trained in internal medicine at Duke University Medical Center and completed a fellowship in oncology at the Dana-Farber Cancer Institute in 2003. Discoveries from his laboratory have led to the first molecular genetic classification of sporadic ccRCC, the identification of a new familial RCC syndrome, the development of the first genetically-engineered mouse model of ccRCC reproducing the genetics of the human disease, and the validation of HIF-2 as a therapeutic target.
Ir arriba


Dr. Ignacio Durán

Hospital Universitario Virgen del Rocío, Sevilla


See curriculum
El Dr. Ignacio Durán trabaja en el Servicio de Oncología Médica del Hospital Universitario Virgen del Rocío de Sevilla. Fue coordinador de docencia y del programa de tumores genitourinarios del centro Integral Oncológico “Clara Campal” del Grupo Hospital de Madrid. Licenciado en Medicina y Cirugía por la Universidad de Salamanca y Doctor por la Universidad Complutense de Madrid. A lo largo de su carrera ha desarrollado estancias formativas en distintos centros investigadores nacionales e internacionales tales como la sede del CSIC de la Universidad de Salamanca, la Universidad Católica del Sacro Cuore de Roma (Italia), el “Centre Hospitalier Universitaire » de Nantes (Francia) y el “Memorial Sloan Kettering Cancer Center” de Nueva York (EE.UU).

Tras su formación clínica en el Hospital Clínico Universitario de Son Dureta (Palma de Mallorca), trabajó en el Servicio de Oncología Médica del Hospital Universitario Doce de Octubre (Madrid) y durante el trienio 2004-2007 en los departamentos de Desarrollo de Nuevos Fármacos y de Tumores Genitourinarios del “Princess Margaret Hospital” de Toronto (Ontario, Canadá).

Durante su estancia en Toronto completo un programa de Máster de docencia orientada a la medicina en la Universidad de Toronto. Es autor de importantes trabajos en diferentes ámbitos de la oncología médica publicados en destacadas revistas científicas. A lo largo de su carrera ha recibido entre otros galardones, el ASCO Foundation Merit Award, el Novartis Young Canadian Investigator Award y el University Health Network Outstanding Research Presentation Award.

Ir arriba


Dr. Karim Fizazi

Institute Gustave-Roussy, Villejuif, France

See curriculum
- September 2009: Full Professor, Institut Gustave Roussy, University of Paris, France.
- Since June 2005: Appointed Head of the Department of Medicine, Institut Gustave Roussy (IGR), France.
- Since 2004: Chairman of the Genito-urinary Oncology Group, Institut Gustave Roussy (IGR), France.
- Since 2001: Assistant Professor in Medical Oncology, Department of Medicine, Institut Gustave Roussy (IGR), France.
- 1999-2001: Visiting Assistant Professor, Genitourinary Medical Oncology Department, MD Anderson cancer Center, Houston, TX, USA.
- 1997-1999: Assistant Professor in Medical Oncology, department of Medicine, Institut Gustave Roussy (IGR), France.
- 1995-1997: Appointed Chef de clinique (Fellow) Medical oncology, Institut Gustave Roussy (IGR), France.
- 1991-1995: Appointed Interne des hôpitaux de Paris (Residency):
- Medical Oncology, Department of Pr Marty, Hôpital St Louis (1995)
- Medical Oncology, Department of Pr Droz and Dr Le Chevalier, IGR (1995)
- Medical Oncology, Department of Pr Pouillart, Institut Curie (1993)
- Medical Oncology, Department of Pr Tursz, IGR (1993)
- Radiotherapy, Department of Pr Cosset, Institut Curie (1992)
- Medical Oncology, Department of Dr Ruffié, IGR (1992)
- Cardiology, Department of Pr Leca, Hôpital Laënnec (1991)
- Emergency, Department of Dr Duliouste, La Rochelle (1991)
- 1994: Diplôme d’Etudes Appliquées: Postgraduate Diploma prior to PhD, Fundamental Bases of Oncogenesis, Pr Tursz’ Laboratory, IGR

- 2003: Ph.D. (Molecular Oncology)
- 1997: « Ancien Chef de Clinique » (Fellowship), Medical Oncology
- 1995: MD (Medical Oncology)
- 1990: Concours de l’Internat de Paris (Competitive Examination) ranked 45 / 3000 candidates, Internal Medicine.
- October 1984 to June 1990: Medical school, University of Poitiers, France

Ir arriba


Dr. Enrique Gallardo

Corporació Sanitària Parc Taulí, Sabadell, Barcelona


See curriculum
Dr. Enrique Gallardo earned his degree in Medicine and Surgery from the University of Seville in 1990. Specialist in Medical Oncology since 1996, after their training at the Hospital General Vall d’Hebron in Barcelona between 1992 and 1995.

He was Attending at Oncology Department at Vall d’Hebron Hospital in 1996 and Clinical Trials Coordinator in the same department between 1996 and 1999, later to be Attending at Oncology Service at Terrassa Hospital in Barcelona until 2002. He is currently Senior Attending Physician at Oncology Department at Corporació Parc Taulí in Sabadell, Barcelona, and responsible for the Uro-Oncology Unit.

He is a member of the Spanish Group for treatment of Genito-Urinary Tumors (SOGUG) where is actively involved in Kidney Cancer and Bladder Cancer Working Groups. He is an active member of the SEOM (Spanish Society of Medical Oncology), ESMO (European Society of Medical Oncology), ASCO (American Society of Clinical Oncology), IASLC (International Association for the Study of Lung Cancer) and EORTC (European Organisation for the Research and Treatment of Cancer), Genito-Urinary Cancer Group.

He has participated as a researcher and designer in many clinical trials in various areas of oncology, especially in urological tumors, including phase I, II, II and IV trials. He has participated in the development of Prostate Cancer OncoGuide in Catalonia and SOGUG Kidney Cancer and Bladder Cancer Guides. He has published around 100 articles, book chapters and communications at national and international meetings.

His areas of expertise include the treatment of urological tumors (kidney, urothelial carcinomas, prostate and germ-cell tumors) and central nervous system neoplasms. He is also interested of other cancer-related areas, such as cancer-related thrombosis and supportive care.

Ir arriba


Dr. Jorge García

Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio


See curriculum
Jorge A. Garcia, MD., FACP, is an Associate Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. A Staff member of the Department of Solid Tumor Oncology and Urology at the Cleveland Clinic Taussig Cancer Institute and Glickman Urological Institute, Dr. Garcia’s work focuses on genitourinary malignancies. He is the current director of the advanced prostate cancer research program at the Cleveland Clinic.
Dr. Garcia earned his medical degree at the Colombian School of Medicine in Bogota, Colombia (South America). After completing a Cancer Biology Fellowship at Harvard Medical School, Dr. Garcia completed his training in Internal Medicine at the Albert Einstein College of Medicine in New York. Subsequently, Dr. Garcia was awarded a fellowship in hematology and oncology and Urologic Oncology at the University of California San Francisco.
Certified in Medical Oncology and Internal Medicine by the American Board of Internal Medicine, Dr. Garcia’s primary research at the Cleveland Clinic has been in prostate, kidney and bladder cancer, with special focus on developmental therapeutics and targeted therapy. Dr. Garcia’s has authored over 100 manuscripts and his research has been published in peer-reviewed journals that include New England Journal of Medicine, Clinical Cancer Research, Journal of Clinical Oncology, Journal of the National Cancer Institute, Lancet Oncology, Journal of Urology, Cancer and BJU International among others. He is a reviewer for several medical journals including, Clinical Cancer Research, Cancer, Urology, Annals of Oncology, Journal of Clinical Oncology, Clinical and Experimental Medicine and the BJU.
Dr. Garcia is a Fellow of the American College of Physicians and serves as a relevance reviewer for the American Board of Internal Medicine. He is also an editor for Urologic Oncology for the American Society of Clinical Oncology (ASCO) and currently serves as the Chair of the Scientific Protocol Review Committee at the Comprehensive Cancer Center at Case Western Reserve University. Dr. Garcia has also been listed among the best doctors in Cleveland and the United Stated every year since 2009.

Ir arriba


Dr. Roberto García-Figueiras

Hospital Clínico Universitario, Santiago de Compostela


See curriculum


Main Research Field

-Oncologic Imaging
-Abdominal/Pelvic Radiology

PhD in the field of FUNCTIONAL AND MOLECULAR IMAGING applied to Oncology (2014): “Valor de las técnicas de imagen funcional y molecular en los tumores” (“The Value of Functional and Molecular Imaging in Tumors”). Qualification: CUM LAUDE

- 6 books chapters published devoted to oncologic imaging
- 17 papers published devoted to oncologic imaging + other 34 radiological papers
- Speaker in many meetings mainly focused on oncologic imaging
- 12 national and international prizes in main radiological meetings
- International Meetings: 64 posters presented
- National Meetings: 53 posters presented

Ir arriba


Dr. Enrique González Billalabeitia

Hospital General Universitario Morales Meseguer, Murcia


See curriculum
Enrique González-Billalabeitia obtained his medical degree at the University of Navarra in 1998; he became specialist in Medical Oncology at “12 de Octubre” university hospital in 2003 and he got his PhD at the University Complutense of Madrid in 2005. He has been a post-doctoral fellow, between 2010 and 2012, in Pandolfi’s lab at the department of genetics in BIDMC/Harvard Medical School focused on prostate cancer research and treatment, and he is currently the coordinator of urology tumors in the department of medical oncology at Morales Meseguer University Hospital in Murcia, Spain. His major focus of research is to better understand prostate cancer biology and to identify new therapies.
Ir arriba


Dra. Aránzazu González del Alba

Hospital Universitario Son Espases, Mallorca


See curriculum
Dr. Aránzazu González del Alba Baamonde holds a Degree in Medicine and Surgery from Madrid Autonomous University (1993).

She completed her training in Clinical Oncology in Son Dureta University Hospital (Palma de Mallorca, 1994-1997) and holds a Master in Molecular Oncology: Molecular bases of Cancer. Molecular Pathology Program of the National Oncological Research Centre (CNIO), recognized by the European School of Oncology (2007-2009).

She is a staff physician of the Department of Clinical Oncology of Son Espases Universitary Hospital and since 2002 she has directed the Unit of Urological and Gynecological tumors.

Since 2009 she forms part of the Steering Committee of the Spanish Oncology Genitourinary Group (SOGUG), coordinating the Teaching Commission.

Ir arriba


Dr. Enrique Grande

Hospital Universitario Ramón y Cajal, Madrid


See curriculum
Enrique Grande is the Director of Research for the Medical Oncology Service and leads the Genitourinary and Endocrine Tumors Unit at Ramón y Cajal University Hospital in Madrid, Spain. Dr Grande received his medical degree from the Autónoma University of Madrid in 1999. From 2001–2005, Dr Grande completed his Residency and Fellowship at the University Hospital Clinico San Carlos in Madrid, under the direction of Professor Diaz-Rubio. He later qualified as a PhD at the Alcalá University thanks to a Spanish National Ministry of Health grant for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors liver metabolism. Dr. Grande also holds a Master Degree in Molecular Biology of Cancer by the Spanish National Oncology Center (CNIO). Dr. Grande has published more than 70 manuscripts in peer review journals Dr. Grande is the editor of several books about Oncology. Dr Grande is currently the Chair of the Spanish Group for Research in Orphan and Infrequent Tumors (GETHI). His research focuses on advances in treatment of gastroenteropancreatic neuroendocrine tumours, renal cell carcinoma, bladder and prostate cancers, and thyroid malignancies.
Ir arriba


Dr. Pablo Maroto

Hospital de la Santa Creu i Sant Pau, Barcelona


See curriculum
Dr. Maroto is a medical oncologist working in the Sant Pau Hospital of Barcelona, Spain since 1999. From his position, Dr. Maroto has been actively working in the uro-oncology arena participating in more than 30 international clinical trials as principal investigator. He is member of different collaborative groups, among them the Spanish Oncology Genito-Urinary Group (SOGUG) where he has collaborated in the elaboration of Spanish Guidelines for the management of prostate, kidney and bladder cancer. Besides, he presently is the Chairman of the Germ Cell Cancer Group, the Spanish collaborative group for the treatment of Germ Cell cancer.
Ir arriba


Dr. Joaquín Mateo

The Royal Marsden NHS Foundation Trust, London, UK


See curriculum
Joaquin Mateo joined the Drug Development Unit at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (London) in 2011. Under the mentorship of Prof. Johann de Bono, he has been working in early phase clinical trials of several PARP inhibitors and compounds targeting the PI3K-AKT-mTOR pathway. His main interest is the implementation of tumor molecular characterisation data into real-time clinical decision-making for patients. He is currently pursuing a PhD at The Institute of Cancer Research (London) focused in assessing the relevance of DNA repair defects in the progression of prostate cancer and how to therapeutically exploit these aberrations, funded by a joint Medical Research Council & Prostate Cancer UK Fellowship award
Ir arriba


Dr. Sumanta Kumar Pal

City of Hope, California, USA


See curriculum
Sumanta Kumar Pal, M.D.
Assistant Professor, Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program

Sumanta Kumar Pal, M.D., is an assistant professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Kidney Cancer Program at City of Hope. Having been appointed to the faculty for just over four years, Dr. Pal has been extremely productive, publishing more than 130 manuscripts in peer-reviewed journals. He has presented his work in multiple international meetings.
Dr. Pal began his college career at the age of 13 through the California State University, Los Angeles Early Entrance Program. He began medical school at the age of 17 at the University of California, Los Angeles (UCLA), where he developed an immediate interest in cancer research. Working in the laboratory of Dennis Slamon, M.D., Ph.D., Dr. Pal examined the breast cancer drug trastuzumab, performing laboratory-based studies to elucidate mechanisms of resistance to the agent. He continued this work during the course of his residency training at UCLA.
After completing his residency, Dr. Pal transitioned to City of Hope where he trained under Robert Figlin, M.D., developing clinical trials and translational studies for genitourinary cancer, principally in the domain of renal cell carcinoma and prostate cancer. He has garnered numerous awards to support his work, including grants from the California Breast Cancer Research Program, the National Comprehensive Cancer Network and the National Institutes of Health. He recently received a Young Investigator Award from the Kidney Cancer Association to recognize his outstanding research in this domain, and further received the 2012 Charles A. Coltman Translational Research Award from the Southwest Oncology Group to support his work in bladder cancer.
Dr. Pal’s vision is to take discoveries made in the laboratory and translate these findings as quickly and efficiently as possible into tangible benefits for patients.

Ir arriba


Dra. Begoña Pérez Valderrama

Hospital Universitario Virgen del Rocío, Sevilla


See curriculum
Dra. Begoña Pérez Valderrama es oncólogo médico en el H.U Virgen del Rocío de Sevilla desde el año 2006. Tutora MIR desde 2008 hasta 2012. Miembro del Comité Ético de Ensayos Clínicos local desde el año 2008 hasta la actualidad. Desde el año 2009 responsable de tumores genitourinarios y desde el año 2012, responsable de tumores cerebrales. Miembro del Grupo Español de Tumores Genitourinarios, del Grupo Español de Investigación de Neuro-Oncología y del Grupo Español de Oncología Médica.
Ir arriba


Dr. Álvaro Pinto

Hospital Universitario La Paz, Madrid


See curriculum
Especialista en Oncología Médica, miembro del Servicio de Oncología Médica del Hospital Universitario La Paz, Madrid. Encargado de la atención a pacientes con tumores urológicos. Doctor en Medicina por la Universidad Autónoma de Madrid. Investigador del Grupo de Oncología Traslacional del Instituto de Investigación IdiPAZ. Miembro activo de ASCO, ESMO, SEOM, SOGUG y Grupo Germinal. Investigador principal de más de 20 ensayos clínicos en el campo de los tumores urológicos.
Ir arriba


Dr. Josep Mª Piulats

Institut Català d’Oncologia, Barcelona


See curriculum
Not available yet
Ir arriba


Dr. Thomas Powles

Barts Cancer Institute, London, UK


See curriculum
Professor Thomas Powles is the Director of St Bartholomew’s Cancer Centre in London. His focus is on drug development in urology cancer with a particular focus on immune therapies. He lead a number of ongoing trials and has written over 200 papers in the field.
Ir arriba


Dr. Javier Puente

Hospital Universitario Clínico San Carlos, Madrid


See curriculum
I am a medical oncologist with special interest and expertise in treating patients who have lung and urinary cancers, particularly those with renal cancer. My research focus is studying new agents to treat advanced disease and evaluating novel agents in combined-modality therapy to treat advanced disease.

I completed my residency in internal medicine/medical oncology at San Carlos Medical Center (Madrid, Spain). I completed a fellowship in Advanced studies graduate [DEA] & Doctoral credits in the Internal Medicine-Medical Oncology Program, Complutense University of Medicine, Madrid (Spain) between 2002-2004, also Doctoral Thesis and PhD degree (Prognostic factors in recurrent breast cancer patients), Complutense University of Medicine, Madrid (Spain) in 2007.

In 2006, I joined San Carlos Universitary Hospital´s Oncology Service. I am an attending physician and Associated Professor of Medicine Department in Complutense University, Madrid (Spain).

I am a member of the committees of the national clinical research groups SOGUG (Spanish Oncologic Genitourinary Group), GECP (Spanish Lung Cancer Group) and GETHI.

I´ve participated in multiples articles and presentations in national and international meetings, book chapters focused in oncology. Prinicipal and sub-investigator in several clinical trials in lung and genitourinary tumors.

Ir arriba


Dr. Brian Rini

Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio


See curriculum
Not available yet
Ir arriba


Dr. Marc Simó

Hospital Universitari de la Vall d’Hebron, Barcelona


See curriculum
Not available yet
Ir arriba